Current
6.1×
5-Year Average
5.7×
All-Time High
11.8×
All-Time Low
2.5×
P/B Ratio daily chart for AstraZeneca (AZN)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/B Ratio for AstraZeneca (AZN) from 2001 to 2025
| 2025 | $272.02B | $48.67B | 5.6× | +0.6× | |
| 2024 | $201.50B | $40.79B | 4.9× | -0.3× | |
| 2023 | $205.72B | $39.14B | 5.3× | -0.4× | |
| 2022 | $211.00B | $37.04B | 5.7× | +1.1× | |
| 2021 | $179.22B | $39.27B | 4.6× | -3.9× | |
| 2020 | $132.51B | $15.62B | 8.5× | -1.6× | |
| 2019 | $132.51B | $13.13B | 10.1× | +2.4× | |
| 2018 | $96.24B | $12.47B | 7.7× | +1.9× | |
| 2017 | $86.83B | $14.96B | 5.8× | +1.2× | |
| 2016 | $68.15B | $14.85B | 4.6× | -0.0× | |
| 2015 | $85.51B | $18.49B | 4.6× | +0.1× | |
| 2014 | $88.89B | $19.63B | 4.5× | +1.4× | |
| 2013 | $73.80B | $23.22B | 3.2× | +0.7× | |
| 2012 | $58.90B | $23.74B | 2.5× | -0.1× | |
| 2011 | $60.73B | $23.25B | 2.6× | -0.2× | |
| 2010 | $65.45B | $23.21B | 2.8× | -0.5× | |
| 2009 | $67.97B | $20.66B | 3.3× | -0.4× | |
| 2008 | $59.37B | $15.91B | 3.7× | -0.5× | |
| 2007 | $62.39B | $14.78B | 4.2× | -1.1× | |
| 2006 | $81.31B | $15.30B | 5.3× | -0.3× | |
| 2005 | $76.74B | $13.60B | 5.6× | +1.5× | |
| 2004 | $60.23B | $14.42B | 4.2× | -1.9× | |
| 2003 | $80.18B | $13.18B | 6.1× | +0.7× | |
| 2002 | $60.25B | $11.17B | 5.4× | -0.5× | |
| 2001 | $81.36B | $13.71B | 5.9× | — |
- 20255.6×
- 20244.9×
- 20235.3×
- 20225.7×
- 20214.6×
- 20208.5×
- 201910.1×
- 20187.7×
- 20175.8×
- 20164.6×
- 20154.6×
- 20144.5×
- 20133.2×
- 20122.5×
- 20112.6×
- 20102.8×
- 20093.3×
- 20083.7×
- 20074.2×
- 20065.3×
- 20055.6×
- 20044.2×
- 20036.1×
- 20025.4×
- 20015.9×
About P/B Ratio at AstraZeneca (AZN)
AstraZeneca (AZN) P/B ratio is 6.1× as of June 5, 2026. The 5-year average is 5.7×. The sector median currently stands at 3.4×. The current ratio is at the 74th percentile of its own 10-year history.
AstraZeneca (AZN) historical P/B ratio has ranged from a low of 2.5× (2012) to a high of 11.8× (2020) in the available daily series.
The price-to-book (P/B) ratio compares a company's market capitalisation to its book value of equity (total shareholders' equity) on the most recent quarterly balance sheet. It is calculated as market cap ÷ book value of equity (equivalent to share price ÷ book value per share). A P/B below 1× implies the market values the business below its accounting net worth; values well above 1× reflect intangible assets, brand value, or a high return on equity.
AstraZeneca P/B Ratio by Year
AstraZeneca P/B Ratio 2025: 5.6×
AstraZeneca (AZN) P/B ratio in 2025 was 5.6×, expanded from 4.9× the prior year.
AstraZeneca P/B Ratio 2024: 4.9×
AstraZeneca (AZN) P/B ratio in 2024 was 4.9×, contracted from 5.3× the prior year.
AstraZeneca P/B Ratio 2023: 5.3×
AstraZeneca (AZN) P/B ratio in 2023 was 5.3×, contracted from 5.7× the prior year.
AstraZeneca P/B Ratio 2022: 5.7×
AstraZeneca (AZN) P/B ratio in 2022 was 5.7×, expanded from 4.6× the prior year.
AstraZeneca P/B Ratio 2021: 4.6×
AstraZeneca (AZN) P/B ratio in 2021 was 4.6×.
Sector peers by P/B Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/B Ratio — table
Healthcare peers of AstraZeneca (AZN), ranked by P/B ratio.
| 2.9× | |
| 2.7× | |
| 2.6× | |
| 2.6× | |
| 2.5× | |
| 2.5× | |
| 2.4× | |
| 2.4× | |
| 2.3× | |
| 1.8× | |
| 1.8× | |
| 1.7× | |
| 1.7× | |
| 1.6× | |
| 1.5× | |
| 1.5× | |
| 1.5× | |
| 1.4× | |
| 1.4× | |
| 1.4× | |
| 1.2× | |
| 1.2× | |
| 1.1× | |
| 1.1× | |
| 0.8× |
- 2.7×
- 2.4×
- 2.3×
- 1.8×
- 1.7×
- 1.4×
- 1.4×
- 1.2×
- 1.1×
- 1.1×
- 0.8×
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric